# A Study of Pyrotinib Plus Vinorelbine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer

> **NCT03933982** · PHASE2 · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 30 (estimated)

## Conditions studied

- Breast Cancer
- Brain Metastases

## Interventions

- **DRUG:** Pyrotinib Plus Vinorelbine

## Key facts

- **NCT ID:** NCT03933982
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-12-22
- **Primary completion:** 2021-12-22
- **Final completion:** 2022-06-22
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2019-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03933982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03933982, "A Study of Pyrotinib Plus Vinorelbine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT03933982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*